Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients

World Journal of Gastroenterology

Volumn 21, Issue 16, 2015, Pages 4933-4945

  Meguro, Makoto ^a   Mizuguchi, Toru ^a   Nishidate, Toshihiko ^a   Okita, Kenji ^a   Ishii, Masayuki ^a   Ota, Shigenori ^a   Ueki, Tomomi ^a   Akizuki, Emi ^a   Hirata, Koichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Des carboxy prothrombin; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; fetoprotein

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; AFP PROTEIN, HUMAN; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; BLOOD; CARCINOMA, HEPATOCELLULAR; CHI SQUARE DISTRIBUTION; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPARATIVE STUDY; COMPLICATION; EVALUATION STUDY; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; UPREGULATION; VIROLOGY;

AGED; ALPHA-FETOPROTEINS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84928409792     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i16.4933     Document Type: Article

References (34)

1. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999;340:798-799 [PMID: 10072416 DOI: 10.1056/NEJM199903113401009]
2. Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681-688 [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9]
3. Liu L, Dong Z, Liang J, Cao C, Sun J, Ding Y, Wu D. As an independent prognostic factor, FAT10 promotes hepatitis B virusrelated hepatocellular carcinoma progression via Akt/GSK3β pathway. Oncogene 2014;33:909-920 [PMID: 23812429 DOI: 10.1038/onc.2013.236]
4. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P, Fisher R. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 2009;15:85-94 [PMID: 19098997 DOI: 10.2119/molmed.2008.00110]
5. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474 [PMID: 20180029 DOI: 10.1245/s10434-010-0985-4]
6. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928 [PMID: 2990661]
7. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755 [PMID: 9731568 DOI: 10.1002/hep. 510280322]
8. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-215 [PMID: 12673442 DOI: 10.1007/s005350300038]
9. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]
10. Mizuguchi T, Kawamoto M, Meguro M, Nakamura Y, Harada K, Kukita K, Hirata K. Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg 2011;15:1433-1439 [PMID: 21607795 DOI: 10.1007/s11605-011-1566-y]
11. Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Kaneoka Y, Maeda A. Prognostic significance of a combination of pre- and posttreatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol 2012;57:1251-1257 [PMID: 22824818 DOI: 10.1016/j.jhep. 2012.07.018]
12. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009;29:502-510 [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957. x]
13. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS. Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation 1963;1:174-180 [PMID: 14010646]
14. Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Trevisani F. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer 2014;120:2150-2157 [PMID: 24723129 DOI: 10.1002/cncr.28706]
15. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-1431 [PMID: 6201741 DOI: 10.1056/NEJM198405313102204]
16. Shimada M, Takenaka K, Fujiwara Y, Gion T, Kajiyama K, Maeda T, Shirabe K, Sugimachi K. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996;78:2094-2100 [PMID: 8918402]
17. Huo TI, Huang YH, Lui WY, Wu JC, Lee PC, Chang FY, Lee SD. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep 2004;11:543-550 [PMID: 14719097]
18. Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol 2009;43:482-488 [PMID: 19197197 DOI: 10.1097/MCG.0b013e318182015a]
19. Shirabe K, Taketomi A, Morita K, Soejima Y, Uchiyama H, Kayashima H, Ninomiya M, Toshima T, Maehara Y. Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transplant 2011;25:E491-E498 [PMID: 21518000 DOI: 10.1111/j.1399-0012.2011.01463.x]
20. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649 [PMID: 4541913]
21. Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg 2005;12:16-22 [PMID: 15754094 DOI: 10.1007/s00534-004-0965-9]
22. Pringle JH. V. Notes on the Arrest of Hepatic Hemorrhage Due to Trauma. Ann Surg 1908;48:541-549 [PMID: 17862242]
23. Chon YE, Choi GH, Lee MH, Kim SU, Kim Do Y, Ahn SH, Kim KS, Choi JS, Han KH, Chon CY, Park JY. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer 2012;131:2332-2341 [PMID: 22362471 DOI: 10.1002/ijc.27507]
24. Hung HH, Su CW, Lai CR, Chau GY, Chan CC, Huang YH, Huo TI, Lee PC, Kao WY, Lee SD, Wu JC. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int 2010;4:691-699 [PMID: 21286339 DOI: 10.1007/s12072-010-9213-3]
25. Ishikawa T. Clinical features of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2010;16:2463-2467 [PMID: 20503445]
26. Kang SH, Kim Do Y, Jeon SM, Ahn SH, Park JY, Kim SU, Kim JK, Lee KS, Chon CY, Han KH. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol 2012;24:849-856 [PMID: 22495400 DOI: 10.1097/MEG.0b013e3283535c34]
27. Fujiyama S, Izuno K, Yamasaki K, Sato T, Taketa K. Determination of optimum cutoff levels of plasma des-gammacarboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves. Tumour Biol 1992;13:316-323 [PMID: 1283927]
28. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL. Des-gamma-carboxy prothrombin and alphafetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493-502 [PMID: 19852963 DOI: 10.1053/j.gastro.2009.10.031]
29. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008;2:17-30 [PMID: 19669276 DOI: 10.1007/s12072-007-9038-x]
30. Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol 2013;19:339-346 [PMID: 23372355 DOI: 10.3748/wjg.v19.i3.339]
31. Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J, Yoshizawa H. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol 2011;46:536-544 [PMID: 21132575 DOI: 10.1007/s00535-010-0349-7]
32. Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol 2011;46:799-808 [PMID: 21373851 DOI: 10.1007/s00535-011-0384-z]
33. Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:989-994 [PMID: 21820396 DOI: 10.1016/j.cgh.2011.07.026]
34. Saito Y, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Yamada S, Asanoma M. Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein. Hepatol Res 2012;42:887-894 [PMID: 22524419 DOI: 10.1111/j.1872-034X.2012.01004.x]